Physician profile
Rene M Duregger
NPI 1245436765
$1,064.84
in general payments reported to CMS, 2019-2025
19 companies · $15.52 in 2025
The $15.52 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $26.20 · 2021: $53.15 · 2022: $103 · 2023: $265 · 2024: $356 · 2025: $15.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $180.86 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $114.17 | 2022-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $101.87 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $69.09 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.98 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $56.56 | 2023-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $56.23 | 2021-2022 | |
| Tris Pharma INC | $50.38 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $48.42 | 2024 | |
| Alkermes, INC. | $47.63 | 2023 | Aristada, Lybalvi |
| Allergan, INC. | $45.01 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $40.80 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $37.01 | 2024 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $35.92 | 2023 | Fanapt, Hetlioz |
| Owp Pharmaceuticals, INC. | $32.87 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.12 | 2019 | |
| Vertical Pharmaceuticals, LLC | $24.61 | 2019 | |
| Neos Therapeutics, LP | $16.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.33 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Duregger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.